news

  • 17 September 2018
    Sequana Medical reports positive data on use of the alfapump® in malignant ascites patients at the International Gynecologic Cancer Society

    Sequana Medical AG (“Sequana Medical”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today positive findings from its Retrospective Malignant Ascites Study.

    The study retrospectively evaluated 17 patients with malignant ascites that had been implanted with the alfapump® in centres across Europe. The study demonstrated that the alfapump® was effective in treating palliative patients with malignant ascites and improving their quality of life.

    The findings of the study were presented by Principal Investigator, Christina Fotopoulou MD, PhD, Imperial College London at the 17th Biennial Meeting of the International Gynecologic Cancer Society that was held from 14-16 September in Kyoto, Japan.

    Prof. Dr. Christina Fotopoulou at Imperial College London commented: “The alfapump® is a novel strategy offering a new opportunity for patients with refractory malignant ascites to have an improved quality of life and a lower need for hospitalisation, so that they can spend more time outside of a hospital environment. It is a very promising, minimally invasive technology that has the potential to significantly improve the quality of life of patients in a very difficult phase of their lives.”

    Ian Crosbie, Chief Executive Officer of Sequana Medical, added: “These data build upon our extensive clinical and commercial experience with the alfapump® in liver refractory ascites and support our growth strategy in malignant ascites. Patients with malignant ascites have a poor prognosis where the impact of ascites on their quality of life is significant, often reducing their ability to withstand further cancer treatments. There is therefore a high unmet need for a therapy that manages malignant ascites and improves patients’ quality of life. We believe that these data demonstrate the compelling potential of the alfapump® to improve clinical outcomes for malignant ascites patients.”

    The data will also be presented at the 68th Annual Meeting of the Society of Pelvic Surgeons being held from 23-29 September 2018 in Bucharest, Romania.